Colorectal cancer Posts on Medivizor
Navigation Menu

Colorectal cancer Posts on Medivizor

Evaluating FOLFIRI plus cetuximab or bevacizumab in advanced colorectal cancer

Evaluating FOLFIRI plus cetuximab or bevacizumab in advanced colorectal cancer

Posted by on Nov 30, 2020 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness of FOLFIRI (5-fluorouracil, folinic acid, and irinotecan) with either cetuximab (Erbitux) or bevacizumab (Avastin) in the treatment of advanced colorectal cancer (CRC). Researchers suggested that FOLFIRI with cetuximab resulted in improved response and longer survival for these patients. Some...

Read More

Irinotecan combined with capecitabine-based chemoradiotherapy before surgery improves the outcomes of patients with rectal cancer

Irinotecan combined with capecitabine-based chemoradiotherapy before surgery improves the outcomes of patients with rectal cancer

Posted by on Nov 29, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of treatment with irinotecan (Camptosar) combined with capecitabine (Xeloda) chemotherapy (ICC) before rectal cancer surgery. Researchers suggested that this combined therapy significantly improved the treatment outcomes in these patients. Some background Rectal cancer is a common...

Read More

Searching for patients with EGFR-positive advanced tumors to trial an experimental treatment.

Searching for patients with EGFR-positive advanced tumors to trial an experimental treatment.

Posted by on Nov 22, 2020 in Colorectal cancer | 0 comments

In a nutshell This trial is being carried out to assess the safety and effectiveness of an experimental drug called BCA101 alone and in combination with pembrolizumab (Keytruda) in advanced solid tumors that are EGFR-positive. The main outcomes to be measured are the occurrence of side effects and response to treatment. The details Advanced solid...

Read More

Evaluating sexual function in men treated with rectal cancer surgery

Evaluating sexual function in men treated with rectal cancer surgery

Posted by on Nov 20, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated the long-term changes in sexual function (SF) in men after rectal cancer surgery. Researchers suggested that SF was not significantly affected by rectal cancer surgery. Some background Colorectal cancer is the third most common cancer worldwide. Of these, around 30% are rectal cancers. Newer cancer therapies...

Read More

Evaluating timing between chemoradiotherapy and surgery in patients with rectal cancer.

Evaluating timing between chemoradiotherapy and surgery in patients with rectal cancer.

Posted by on Nov 15, 2020 in Colorectal cancer | 0 comments

In a nutshell This trial was carried out to examine the optimal time interval between completing chemoradiotherapy (CRT) and robotic-assisted surgery (RAS) in patients with rectal cancer. The trial found that RAS is safe and effective after 10-12 weeks of CRT. Some background Rectal cancer treatment has experienced an improvement with new...

Read More

Colorectal cancer surgery and long-term health related quality of life with remote follow-up

Colorectal cancer surgery and long-term health related quality of life with remote follow-up

Posted by on Nov 7, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated the long-term health-related quality of life (HQL) after colorectal cancer (CRC) surgery. Researchers suggested that overall long-term HQL was good, although some patients may need closer follow-up. Some background CRC is the third most common cancer worldwide. Surgery is the recommended treatment and is...

Read More

Evaluating the timing of chemotherapy plus bevacizumab for patients with colorectal cancer and liver metastasis

Evaluating the timing of chemotherapy plus bevacizumab for patients with colorectal cancer and liver metastasis

Posted by on Oct 24, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated whether chemotherapy plus bevacizumab (Avastin) before and after or after surgery improves the survival of patients with colorectal cancer (CRC) and operable liver metastasis (LM; cancer spread to the liver). Researchers suggested that chemotherapy and bevacizumab before and after...

Read More

Evaluating Immunoscore as a prognostic factor in stage 3 colon cancer

Evaluating Immunoscore as a prognostic factor in stage 3 colon cancer

Posted by on Oct 10, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated Immunoscore (IMS) as a prognostic tool in patients with stage 3 colon cancer. Researchers suggested that a high IMS is associated with prolonged survival in these patients. Some background Colorectal cancer is the third most common cancer worldwide. A significant percentage of patients present with high-risk...

Read More

Three different treatments for metastatic colorectal cancer: a comparison.

Three different treatments for metastatic colorectal cancer: a comparison.

Posted by on Oct 4, 2020 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness of three different treatments for metastatic (spread to other parts of the body) colorectal cancer (mCRC). Researchers suggested that fruquintinib (Elunate) was associated with the best treatment outcomes. Some background Colorectal cancer is a common cancer worldwide and 25% of patients present with...

Read More

Comparing regorafenib plus chemotherapy to other biological drugs for the second-line treatment of metastatic colorectal cancer

Comparing regorafenib plus chemotherapy to other biological drugs for the second-line treatment of metastatic colorectal cancer

Posted by on Sep 30, 2020 in Colorectal cancer | 0 comments

In a nutshell This analysis was carried out to look at including regorafenib (Stivarga) in second-line therapy for patients with metastatic colorectal cancer (mCRC). The authors found that regorafenib in combination with chemotherapy might be an alternative to standard second-line treatment options for these patients. Some...

Read More

FOLFOXIRI plus bevacizumab improves survival of patients with advanced colorectal cancer

FOLFOXIRI plus bevacizumab improves survival of patients with advanced colorectal cancer

Posted by on Sep 19, 2020 in Colorectal cancer | 0 comments

In a nutshell This study compared the survival outcomes of different chemotherapy treatments in patients with inoperable advanced colorectal cancer (CRC). Researchers suggested that FOLFOXIRI plus bevacizumab (Avastin) significantly improved the survival of these patients. Some background Around 20% of patients present with advanced CRC at diagnosis....

Read More